PDI guided lower for the third quarter and full year, but CEO Nancy Lurker, says now is the time for investors to look at the company as it just made its first acquisition in the molecular diagnostic space, which has the potential for more growth and higher margins than PDI’s traditional core business and she is bullish on where the new vertical will take the company. Lurker believes the diagnostic business is indicative of what we see happening in healthcare overall with the explosion of personalized healthcare and genomics. Earlier diagnosis of disease will ultimately save the healthcare system more money and impact patient care more positively.

If you liked this article you might like

Insider Trading Alert - PDII, SSI And FBIZ Traded By Insiders

3 Diversified Services Stocks Driving The Industry Higher

3 Stocks Pushing The Diversified Services Industry Lower

3 Diversified Services Stocks Pushing The Industry Higher

3 Stocks Pushing The Diversified Services Industry Lower